Literature DB >> 1901260

Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.

J P Nadler1, J Berger, J A Nord, R Cofsky, M Saxena.   

Abstract

This report describes two patients with multidrug resistant tuberculosis who were successfully treated with the addition of amoxicillin-clavulanic acid to second-line drugs. Mycobacterium tuberculosis possesses a beta-lactamase contributing to its resistance to beta-lactam antibiotics. The combination of clavulanic acid, a beta-lactamase inhibitor, and amoxicillin has been shown bactericidal for M tuberculosis in vitro. These data suggest that resistant tuberculosis may warrant a trial of treatment including amoxicillin-clavulanic acid.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1901260     DOI： 10.1378/chest.99.4.1025

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


  37 in total

1.  Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis.

Authors:  Sanjib Bhakta; Joyoti Basu
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

2.  Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Authors:  Shiqi Xiao; Haidan Guo; Warren S Weiner; Clinton Maddox; Chunhong Mao; Hendra Gunosewoyo; Shaaretha Pelly; E Lucile White; Lynn Rasmussen; Frank J Schoenen; Jeffrey Aubé; William R Bishai; Shichun Lun
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

3.  Biochemical characterization of the 49 kDa penicillin-binding protein of Mycobacterium smegmatis.

Authors:  T Mukherjee; D Basu; S Mahapatra; C Goffin; J van Beeumen; J Basu
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

4.  Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.

Authors:  C J Hackbarth; I Unsal; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Withdrawn

Authors: 
Journal:  Infect Disord Drug Targets       Date:  2012-11-16

6.  Oldie but goodie: Repurposing penicillin for tuberculosis.

Authors:  Amanda B Keener
Journal:  Nat Med       Date:  2014-09       Impact factor: 53.440

7.  In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors.

Authors:  Yasuhiro Horita; Shinji Maeda; Yuko Kazumi; Norio Doi
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

8.  Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  C Segura; M Salvadó; I Collado; J Chaves; A Coira
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin.

Authors:  Radhika Gupta; Marie Lavollay; Jean-Luc Mainardi; Michel Arthur; William R Bishai; Gyanu Lamichhane
Journal:  Nat Med       Date:  2010-03-21       Impact factor: 53.440

10.  Clinical effects of gemifloxacin on the delay of tuberculosis treatment.

Authors:  Seo Yun Kim; Jae-Joon Yim; Jong Sun Park; Sung Soo Park; Eun Young Heo; Chang-Hoon Lee; Hee Soon Chung; Deog Kyeom Kim
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.